



Supplementary Fig. 6 Mn^{2+} boosts antitumor immunotherapy in mice. **a** Tumor sizes of subcutaneous MC38 implants in mice treated with the isotype antibody (200 $\mu\text{g}/\text{mouse}$ i.p.), MnCl_2 (5 mg/kg i.v.), anti-PD-1 antibody (200 $\mu\text{g}/\text{mouse}$ i.p.) or MnCl_2 plus anti-PD-1 antibody ($n=6$ per group). **b** Representative images (left), tumor sizes (middle) and tumor weights (right) of subcutaneous MC38 implants in mice as in (a). **c** MC38 tumors from (b) were stained with anti-CD8-FITC and counterstained with DAPI. Scale bar, 50 μm . **d** The indicated organs from

B16F10 tumor-bearing mice treated with MnCl₂ (5 mg/kg i.p.), anti-PD-1 antibody (200 µg/mouse i.p.) or MnCl₂ plus anti-PD-1 antibody (Combo, n=5 per group) were examined by H & E staining at day 16. Data represent analyses of the indicated n mice per group, mean ± SEM. Data are representative of three independent experiments. ns, not significant, p>0.05; *p < 0.05; **p < 0.01; ***p < 0.001.